Skip to main content
Clinical Trials/ACTRN12624000772549
ACTRN12624000772549
Not yet recruiting
Phase 1

A pilot study to evaluate the effectiveness of intranasal Botulinum Toxin Type A Spray for adult patients with Rhinitis

Metro North Hospital and Health Service0 sites15 target enrollmentJune 25, 2024

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Allergic Rhinitis
Sponsor
Metro North Hospital and Health Service
Enrollment
15
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 25, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients greater than or equal to 18 years
  • 2\. Clinically confirmed diagnosis of allergic or non\-allergic rhinitis.
  • 3\. Prior Radioallergosorbent test (RAST) test and immunoglobulin E ( IgE) level (as part of the patient’s standardised medical treatment).
  • 4\. Incomplete management of symptoms despite appropriate medical treatment (intra\-nasal corticosteroid and nasal douching)

Exclusion Criteria

  • 1\. Patients less than 18 years
  • 2\. Participants who are unable to provide informed consent.
  • 3\. Participants who are pregnant, breast feeding or planning to become pregnant during study.
  • 4\. Participants with an absolute contraindication to botulinum toxin type A specifically allergy, pregnancy, coexisting myasthenia gravis.
  • 5\. Coexisting chronic rhinosinusitis.
  • 6\. Subjects with known hypersensitivity or contraindications to mometasone nasal spray.
  • 7\. Participants who have been on an active investigational therapy within 1 month prior to screening
  • 8\. Women of childbearing potential who are not willing to use double barrier method of contraception during the study. That is:
  • \-Use of contraceptive pill or intrauterine device (IUD) or similar
  • \-and Condoms

Outcomes

Primary Outcomes

Not specified

Similar Trials